Get started
Author

Jens Fritsche

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
2014 · Mahesh Yadav, Suchit Jhunjhunwala, et al. · Nature · 1,196
Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 948
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
2012 · Steffen Walter, Toni Weinschenk, et al. · Nature Medicine · 802
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
2016 · Brian I Rini, Arnulf Stenzl, et al. · The Lancet Oncology · 228
Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits
2010 · Xinjie Zhao, Jens Fritsche, et al. · Metabolomics · 210
PDF
Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy
2012 · Valérie Dutoit, Christel Herold-Mende, et al. · Brain · 202
PDF
Practical Approach for the Identification and Isomer Elucidation of Biomarkers Detected in a Metabonomic Study for the Discovery of Individuals at Risk for Diabetes by Integrating the Chromatographic and Mass Spectrometric Information
2008 · Jing Chen, Xinjie Zhao, et al. · Analytical Chemistry · 191
Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at?
2008 · Xinjie Zhao, Andreas Peter, et al. · American Journal of Physiology-Endocrinology and Metabolism · 174
RNA editing derived epitopes function as cancer antigens to elicit immune responses
2018 · Minying Zhang, Jens Fritsche, et al. · Nature Communications · 154
PDF
Medium Chain Acylcarnitines Dominate the Metabolite Pattern in Humans under Moderate Intensity Exercise and Support Lipid Oxidation
2010 · Rainer Lehmann, Xinjie Zhao, et al. · PLoS ONE · 154
PDF
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance
2017 · Norma Bloy, Pauline Garcia, et al. · Immunological Reviews · 106
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 78
Metabonomics Study on the Effects of the Ginsenoside Rg3 in a β-Cyclodextrin-Based Formulation on Tumor-Bearing Rats by a Fully Automatic Hydrophilic Interaction/Reversed-Phase Column-Switching HPLC−ESI-MS Approach
2008 · Yuan Wang, Jiangshan Wang, et al. · Analytical Chemistry · 78
Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy
2022 · Gloria B. Kim, Jens Fritsche, et al. · Science Translational Medicine · 41
PDF
Translating Immunopeptidomics to Immunotherapy‐Decision‐Making for Patient and Personalized Target Selection
2018 · Jens Fritsche, Barbara Rakitsch, et al. · PROTEOMICS · 41
PDF
Pitfalls in HLA Ligandomics—How to Catch a Li(e)gand
2021 · Jens Fritsche, Daniel J. Kowalewski, et al. · Molecular & Cellular Proteomics · 31
17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC
2015 · B. Rini, A. Stenzl, et al. · European Journal of Cancer · 20
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2023 · Apostolia M. Tsimberidou, Kerstin Guenther, et al. · Cancer Immunology Research · 16
PDF
IMA901 Multipeptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC.
2011 · B. I. Rini, T. Eisen, et al. · Journal of Clinical Oncology · 16
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
2019 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 15
PDF
Macrophages in tumor biology
2002 · M Kreutz, J Fritsche, et al. · Oxford University Press eBooks · 12
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 7
PDF
293 Resultsof the first-in-human clinical trial with personalized multi-target adoptive cell therapy (ACTolog IMA101)
2020 · Apostolia Tsimberidou, Kerstin Guenther, et al. · Journal for ImmunoTherapy of Cancer · 2
Abstract 2789: Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands
2018 · Sebastian Bunk, Martin Hofmann, et al. · Cancer Research · 2
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers
2018 · A.-M. Tsimberidou, H. Ma, et al. · Annals of Oncology · 1
Works count: 112
Citation count: 4,729
H-index: 17
I10-index: 21
Year
Topic
Type